HIGH-ACTIVITY I-125 INTERSTITIAL IRRADIATION IN THE TREATMENT OF PEDIATRIC CENTRAL-NERVOUS-SYSTEM TUMORS - A PILOT-STUDY

被引:4
|
作者
FONTANESI, J
HEIDEMAN, RL
MUHLBAUER, M
MULHERN, R
SANFORD, RA
DOUGLASS, EC
KOVNAR, E
OCHS, JJ
KUTTESCH, JF
TAI, D
KUN, LE
机构
[1] ST JUDE CHILDRENS RES HOSP, DEPT RADIAT ONCOL, MEMPHIS, TN 38105 USA
[2] ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, MEMPHIS, TN 38105 USA
[3] ST JUDE CHILDRENS RES HOSP, DEPT NEUROL, MEMPHIS, TN 38105 USA
[4] ST JUDE CHILDRENS RES HOSP, DIV BEHAV MED, MEMPHIS, TN 38105 USA
[5] UNIV TENNESSEE, COLL MED, DEPT RADIOL, MEMPHIS, TN USA
[6] UNIV TENNESSEE, COLL MED, DEPT NEUROSURG, MEMPHIS, TN USA
[7] UNIV TENNESSEE, COLL MED, DEPT PEDIAT, MEMPHIS, TN USA
[8] ST CHRISTOPHERS HOSP CHILDREN, PHILADELPHIA, PA 19133 USA
关键词
I-125; BRAIN TUMORS; INTERSTITIAL IMPLANTS; PEDIATRIC TUMORS;
D O I
10.1159/000120918
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Malignant pediatric tumors of the central nervous system (CNS) have a poor prognosis, with local failure rates as high as 50%, In an attempt to improve local tumor control, we used stereotactic interstitial therapy with I-125 implants in patients with recurrent/secondary or newly diagnosed CNS malignancies, Catheters were placed using computed tomography (CT) guidance; computerized dosimetry was completed with the aid of orthogonal films. Implants delivered 1,000 cGy/day to the tumor periphery (0.5 cm beyond the boundary of enhancement on CT scans), to a total dose of 60 Gy, Hyperfractionated external beam irradiation (HEBI), started 2-4 weeks after removal of implants, delivered total doses of 66-70.4 Gy in 110-cGy fractions twice daily to a 3-cm margin around the implant volume, Eight of the 1 1 patients with newly diagnosed tumors also received 48.4 Gy HEBI to the craniospinal axis. Tumor regression was noted at 2 months after implantation in the 4 patients treated for recurrent/secondary tumors; local progression was subsequently documented in 2 cases at 6 and 20 months after implantation, while a third patient died 6 months after implantation with no evidence of local recurrence. The remaining recurrent/secondary tumor patient has no evidence of active recurrence 15 months after implantation. Local control was maintained in 9 of the 1 1 patients treated for primary tumors for a median of 27 months (range 15 to 48+ months). The two local failures occurred at 5 and 7 months after implantation. Six patients are alive without evidence of progressive disease (median = 23 months after implantation), There were no severe acute toxicities, but 7 patients later developed histologically confirmed tumor necrosis, Quality of life assessment (QLA) following initial primary therapy with implantation was evaluated utilizing an established criteria and found to be excellent with only one child showing marked QLA score decrease which was related to neurosurgical intervention for radiation-induced necrosis and dysfunctional family social situation, This small series suggests that stereotactic I-125 implantation followed by HEBI merits further evaluation in selected children with supratentorial malignant lesions.
引用
收藏
页码:289 / 297
页数:9
相关论文
共 50 条
  • [31] Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study
    Roger J. Packer
    Brian R. Rood
    David C. Turner
    Clinton F. Stewart
    Michael Fisher
    Christopher Smith
    Tina Young-Pouissant
    Stewart Goldman
    Rishi Lulla
    Anu Banerjee
    Ian Pollack
    Larry Kun
    Arzu Onar-Thomas
    Shengjie Wu
    James M. Boyett
    Maryam Fouladi
    Journal of Neuro-Oncology, 2015, 121 : 217 - 224
  • [32] A pediatric and young adult phase I dose escalation study of BXQ-350 for solid and central nervous system tumors.
    Abdelbaki, Mohamed
    Setty, Bhuvana
    DeWire, Mariko Dawn
    Cripe, Timothy P.
    Curry, Richard
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [33] Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study
    Packer, Roger J.
    Rood, Brian R.
    Turner, David C.
    Stewart, Clinton F.
    Fisher, Michael
    Smith, Christopher
    Young-Pouissant, Tina
    Goldman, Stewart
    Lulla, Rishi
    Banerjee, Anu
    Pollack, Ian
    Kun, Larry
    Onar-Thomas, Arzu
    Wu, Shengjie
    Boyett, James M.
    Fouladi, Maryam
    JOURNAL OF NEURO-ONCOLOGY, 2015, 121 (01) : 217 - 224
  • [34] A phase 1/2 dose-finding, safety, and activity study of cabazitaxel in pediatric patients with refractory solid tumors including tumors of the central nervous system
    Manley, Peter E.
    Trippett, Tanya
    Smith, Amy A.
    Macy, Margaret E.
    Leary, Sarah E. S.
    Boklan, Jessica
    Cohen, Kenneth J.
    Goldman, Stewart
    Kilburn, Lindsay B.
    Dhall, Girish
    Devin, Jeanne
    Herzog, Cynthia E.
    Partap, Sonia
    Fauchet, Floris
    Badreddine, Emmy
    Bernard, John P.
    Chi, Susan N.
    PEDIATRIC BLOOD & CANCER, 2018, 65 (09)
  • [36] PHASE I STUDY OF COMBINATION THERAPY WITH BEVAZICUMAB, IRINOTECAN, AND TEMOZOLOMIDE IN CHILDREN WITH HIGH GRADE AND RECURRENT CENTRAL NERVOUS SYSTEM TUMORS
    Stapleton, Stacie
    Flanary, Jennifer
    Hamblin, Frances
    Steinbrueck, Sonja
    Rodriguez, Luis
    Tuite, Gerald
    Carey, Carolyn
    Storrs, Bruce
    Lavey, Robert
    NEURO-ONCOLOGY, 2012, 14 : 16 - 16
  • [37] A PEDIATRIC AND YOUNG ADULT PHASE I DOSE ESCALATION SAFETY STUDY OF BXQ-350 FOR REFRACTORY SOLID AND CENTRAL NERVOUS SYSTEM TUMORS
    Setty, Bhuvana
    AbdelBaki, Mohamed
    DeWire, Mariko
    Cripe, Timothy
    Curry, Rich
    NEURO-ONCOLOGY, 2020, 22 : 60 - 61
  • [38] Treatment of pediatric high-grade central nervous system tumors with high-dose methotrexate in combination with multiagent chemotherapy: A single-institution experience
    Bernstock, Joshua D.
    Alva, Elizabeth
    Cohen, Joshua L.
    Lobbous, Mina
    Chagoya, Gustavo
    Elsayed, Galal A.
    Orr, Brent A.
    Rozzelle, Curtis
    Rocque, Brandon
    Blount, Jeffrey
    Johnston, James M.
    Li, Rong
    Fiveash, John B.
    Dhall, Girish
    Reddy, Alyssa T.
    Friedman, Gregory K.
    PEDIATRIC BLOOD & CANCER, 2020, 67 (03)
  • [39] PILOT STUDY OF SYSTEMIC AND INTRATHECAL CHEMOTHERAPY FOLLOWED BY CONFORMAL RADIATION FOR INFANTS WITH EMBRYONAL INTRACRANIAL CENTRAL NERVOUS SYSTEM TUMORS: A PEDIATRIC BRAIN TUMOR CONSORTIUM TRIAL
    Blaney, Susan M.
    Kocak, Mehmet
    Heideman, Richard
    Gajjar, Amar
    Kieran, Mark W.
    Phillips, Peter
    McLendon, Roger
    Boyett, James
    Kun, Larry
    NEURO-ONCOLOGY, 2009, 11 (05) : 636 - 636
  • [40] Pilot study of systemic and intrathecal mafosfamide followed by conformal radiation for infants with intracranial central nervous system tumors: a pediatric brain tumor consortium study (PBTC-001)
    Blaney, Susan M.
    Kocak, Mehmet
    Gajjar, Amar
    Chintagumpala, Murali
    Merchant, Thomas
    Kieran, Mark
    Pollack, Ian F.
    Gururangan, Sri
    Geyer, Russ
    Phillips, Peter
    McLendon, Roger E.
    Packer, Roger
    Goldman, Stewart
    Banerjee, Anu
    Heideman, Richard
    Boyett, James M.
    Kun, Larry
    JOURNAL OF NEURO-ONCOLOGY, 2012, 109 (03) : 565 - 571